<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neuropsychopharmacology</journal-id>
<journal-id journal-id-type="iso-abbrev">Neuropsychopharmacology</journal-id>
<journal-title-group>
<journal-title>Neuropsychopharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0893-133X</issn>
<issn pub-type="epub">1740-634X</issn>
<publisher>
<publisher-name>Nature Publishing Group</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29090685</article-id>
<article-id pub-id-type="pmc">5916349</article-id>
<article-id pub-id-type="pii">npp2017258</article-id>
<article-id pub-id-type="doi">10.1038/npp.2017.258</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, An Interleukin-6 Receptor Antibody, For Residual Symptoms in Schizophrenia</article-title>
<alt-title alt-title-type="running">Tocilizumab in schizophrenia</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Girgis</surname>
<given-names>Ragy R</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="corresp" rid="caf1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ciarleglio</surname>
<given-names>Adam</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Choo</surname>
<given-names>Tse</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Haynes</surname>
<given-names>Gregory</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bathon</surname>
<given-names>Joan M</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cremers</surname>
<given-names>Serge</given-names>
</name>
<xref ref-type="aff" rid="aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kantrowitz</surname>
<given-names>Joshua T</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="aff" rid="aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lieberman</surname>
<given-names>Jeffrey A</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brown</surname>
<given-names>Alan S</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<aff id="aff1"><label>1</label><institution>Department of Psychiatry, College of Physicians and Surgeons, Columbia University</institution>, New York, NY, <country>USA</country></aff>
<aff id="aff2"><label>2</label><institution>New York State Psychiatric Institute</institution>, New York, NY, <country>USA</country></aff>
<aff id="aff3"><label>3</label><institution>Department of Medicine, Columbia University</institution>, New York, NY, <country>USA</country></aff>
<aff id="aff4"><label>4</label><institution>Department of Pathology, Columbia University</institution>, New York, NY, <country>USA</country></aff>
<aff id="aff5"><label>5</label><institution>Schizophrenia Research Center, Nathan Kline Institute for Psychiatric Research</institution>, Orangeburg, NY, <country>USA</country></aff>
</contrib-group>
<author-notes>
<corresp id="caf1"><label>*</label><institution>Department of Psychiatry, Columbia University College of Physicians and Surgeons</institution>, 1051 Riverside Drive, Unit 31, New York 10032, NY, <country>USA</country>. Tel: +1 646 774 5553; Fax: +1 646 774 5237; E-mail: <email>ragy.girgis@nyspi.columbia.edu</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>05</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epreprint">
<day>01</day>
<month>11</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>13</day>
<month>12</month>
<year>2017</year>
</pub-date>
<volume>43</volume>
<issue>6</issue>
<fpage>1317</fpage>
<lpage>1323</lpage>
<history>
<date date-type="received">
<day>30</day>
<month>07</month>
<year>2017</year>
</date>
<date date-type="rev-recd">
<day>01</day>
<month>10</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>24</day>
<month>10</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2018 American College of Neuropsychopharmacology</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>American College of Neuropsychopharmacology</copyright-holder>
</permissions>
<abstract>
<p>Evidence from preclinical, epidemiological, and human studies indicates that inflammation, and in particular elevated interleukin-6 (IL-6) activity, may be related to clinical manifestations and pathophysiology of schizophrenia. Furthermore, studies in preclinical models suggest that decreasing IL-6 activity may mitigate or reverse some of these deficits. The purpose of this trial was to test whether an IL-6 receptor antibody, tocilizumab, would improve residual positive and negative symptoms and cognitive deficits in schizophrenia. We randomized 36 clinically stable, moderately symptomatic (i.e., Positive and Negative Syndrome Scale (PANSS) <underline>&gt;</underline>60) individuals with schizophrenia to 3 monthly infusions of 8 mg/kg tocilizumab or placebo (normal saline). The primary outcome was effect at week 12 on the PANSS Total Score. Effects on the MATRICS, other PANSS subscales, Clinical Global Impression, and Global Assessment of Functioning were secondary outcomes. There were no observed treatment effects on any behavioral outcome measure. Baseline C-reactive protein (CRP) or cytokine levels did not predict treatment outcome, nor were there correlations between changes in these inflammatory markers and the measured outcomes. As expected, IL-6 and IL-8 increased, while CRP decreased, in the tocilizumab group compared with the placebo group. This study did not reveal any evidence that an IL-6 receptor antibody affects behavioral outcomes in schizophrenia. One potential explanation is the lack of capacity of this agent to penetrate the central nervous system. Additional trials of medications aimed at targeting cytokine overactivity that act directly on brain function and/or treatment in early-stage psychosis populations are needed.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>